BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Strategic CMO Appointment of Dr. Doron Sagman

December 14, 2021 12:43:10

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced its appointment of Doron Sagman, MD, FRCPC, as the company’s new chief medical officer (“CMO”). Per the update, Dr. Joel Raskin, who was acting CMO, will transition into an advisory role for MINDCURE. As CMO, Dr. Sagman will play a key role in furthering MINDCURE’S mission to reinvent the mental health care model for patients and practitioners and advancing psychedelic-assisted therapy into common and accepted care. “Dr. Sagman’s distinguished career in both mental health and the pharmaceutical industries will enable him to lead the development of innovative therapies to potentially treat a range of mental health conditions,” said Kelsey Ramsden, president and CEO of MINDCURE. “His proven experience as a leader who has built and led diverse teams, as well as his deep understanding of the drug research and development process, will be critical as MINDCURE advances on our path to research digital therapeutic and neuro-supportive solutions.”

To view the full press release, visit

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork